Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abingdon Health PLC ( (GB:ABDX) ) has shared an announcement.
Abingdon Health plc has secured a significant contract with US-based Find Out From Home LLC to handle regulatory and clinical trial services for four sexually transmitted disease tests. Valued at up to $2 million, the contract will aid in the commercialization of these tests in the US, UK, and EU, potentially strengthening Abingdon’s market position in the growing global STD testing market, which is projected to expand significantly in the coming years.
More about Abingdon Health PLC
Abingdon Health plc is a leading Medtech contract service provider headquartered in York, England. The company specializes in the development, regulatory support, and manufacturing of lateral flow diagnostic tests and offers a range of services to the in vitro diagnostic and wider medical device industry. Abingdon Health’s offerings include the Abingdon Simply Test, an e-commerce platform for self-diagnostic tests, and a CDMO division that supports projects from concept to large-scale manufacturing across various sectors such as infectious disease, animal health, and environmental testing.
YTD Price Performance: -31.82%
Average Trading Volume: 159,945
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £14.52M
See more insights into ABDX stock on TipRanks’ Stock Analysis page.
